Blue Owl Capital Holdings LP grew its holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,653,040 shares of the company's stock after purchasing an additional 486,211 shares during the quarter. Larimar Therapeutics comprises 4.2% of Blue Owl Capital Holdings LP's portfolio, making the stock its 10th biggest holding. Blue Owl Capital Holdings LP owned approximately 7.29% of Larimar Therapeutics worth $18,007,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Larimar Therapeutics in the fourth quarter valued at about $52,000. Virtu Financial LLC acquired a new stake in shares of Larimar Therapeutics in the third quarter valued at about $71,000. SG Americas Securities LLC grew its position in shares of Larimar Therapeutics by 35.1% in the fourth quarter. SG Americas Securities LLC now owns 19,391 shares of the company's stock valued at $75,000 after purchasing an additional 5,042 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Larimar Therapeutics by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 19,657 shares of the company's stock valued at $76,000 after purchasing an additional 6,701 shares during the last quarter. Finally, AXQ Capital LP acquired a new stake in shares of Larimar Therapeutics in the fourth quarter valued at about $91,000. 91.92% of the stock is owned by institutional investors and hedge funds.
Larimar Therapeutics Price Performance
Shares of NASDAQ:LRMR traded up $0.07 during trading on Tuesday, reaching $2.42. The stock had a trading volume of 482,781 shares, compared to its average volume of 693,313. Larimar Therapeutics, Inc. has a 52 week low of $1.61 and a 52 week high of $11.20. The business's 50-day moving average price is $2.39 and its 200 day moving average price is $4.34. The stock has a market capitalization of $154.63 million, a PE ratio of -2.10 and a beta of 0.91.
Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.16). Analysts forecast that Larimar Therapeutics, Inc. will post -1.15 EPS for the current year.
Analysts Set New Price Targets
LRMR has been the topic of a number of recent research reports. Robert W. Baird decreased their target price on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. HC Wainwright lifted their target price on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, March 25th. Truist Financial initiated coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They set a "buy" rating and a $18.00 target price on the stock. Guggenheim reissued a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Finally, Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $19.63.
Get Our Latest Stock Report on LRMR
About Larimar Therapeutics
(
Free Report)
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
See Also
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
